Brokers Issue Forecasts for Sage Therapeutics, Inc.’s FY2026 Earnings (NASDAQ:SAGE)

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Analysts at Oppenheimer issued their FY2026 earnings estimates for shares of Sage Therapeutics in a research report issued on Wednesday, January 12th. Oppenheimer analyst J. Olson anticipates that the biopharmaceutical company will post earnings per share of $0.13 for the year. Oppenheimer has a “Outperform” rating and a $80.00 price target on the stock.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, November 2nd. The biopharmaceutical company reported ($2.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.84) by ($0.37). Sage Therapeutics had a negative return on equity of 23.76% and a net margin of 57.61%. The business had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.00 million. During the same quarter in the previous year, the business posted ($2.03) EPS.

SAGE has been the subject of a number of other research reports. Needham & Company LLC boosted their price objective on Sage Therapeutics from $79.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, January 6th. Mizuho reduced their price objective on Sage Therapeutics from $52.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, November 18th. Jefferies Financial Group cut Sage Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $100.00 to $50.00 in a report on Wednesday, October 6th. SVB Leerink reduced their price objective on Sage Therapeutics from $70.00 to $60.00 and set a “market perform” rating for the company in a report on Monday, December 20th. Finally, Guggenheim upgraded Sage Therapeutics from a “neutral” rating to a “buy” rating and set a $55.00 price objective for the company in a report on Tuesday, November 2nd. Eleven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $70.29.

Shares of NASDAQ:SAGE opened at $42.93 on Thursday. Sage Therapeutics has a 12-month low of $36.13 and a 12-month high of $98.39. The stock has a market cap of $2.53 billion, a PE ratio of 3.43 and a beta of 1.75. The business has a 50 day moving average of $41.04 and a 200-day moving average of $44.15.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP raised its position in Sage Therapeutics by 16.5% during the third quarter. Wellington Management Group LLP now owns 6,769,933 shares of the biopharmaceutical company’s stock valued at $299,976,000 after purchasing an additional 957,993 shares in the last quarter. Vanguard Group Inc. raised its position in Sage Therapeutics by 1.4% during the second quarter. Vanguard Group Inc. now owns 4,824,810 shares of the biopharmaceutical company’s stock valued at $274,097,000 after purchasing an additional 66,772 shares in the last quarter. Bellevue Group AG raised its position in Sage Therapeutics by 35.7% during the third quarter. Bellevue Group AG now owns 3,209,004 shares of the biopharmaceutical company’s stock valued at $142,191,000 after purchasing an additional 844,800 shares in the last quarter. BlackRock Inc. raised its position in Sage Therapeutics by 0.8% during the third quarter. BlackRock Inc. now owns 2,874,555 shares of the biopharmaceutical company’s stock valued at $127,371,000 after purchasing an additional 24,057 shares in the last quarter. Finally, State Street Corp raised its position in Sage Therapeutics by 6.3% during the second quarter. State Street Corp now owns 1,336,758 shares of the biopharmaceutical company’s stock valued at $75,941,000 after purchasing an additional 79,368 shares in the last quarter. Institutional investors and hedge funds own 86.94% of the company’s stock.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders.

See Also: Hedge Funds – How They Work For Investors

Earnings History and Estimates for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.